$ERNA

$2.07▲ -1.9% YTD

9 SEC 13D/G filings tracked · Last updated Oct 22, 2026

Filing History

CP $2.07▲ -1.9%Oct 22, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment…

News

ERNA ▼ -9.9% - Ernexa Therapeutics Inc.

CP $2.18▲ -9.9%Oct 12, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series…

News

ERNA ▼ -2.5% - Ernexa Therapeutics Inc.

CP $2.70▲ -2.5%Oct 6, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hoste…

News

ERNA ▼ -0.9% - Ernexa Therapeutics Inc.

CP $3.15▲ -0.9%Oct 1, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward…

News

ERNA ▲ +10.4% - Ernexa Therapeutics Inc.

CP $3.49▲ +10.4%Sep 30, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IN…

News

ERNA ▲ +5.2% - Ernexa Therapeutics Inc.

CP $3.65▲ +5.2%Sep 29, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy…

News

ERNA ▲ +5.1% - Ernexa Therapeutics Inc.

CP $4.10▲ +5.1%Sep 17, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors…

News

ERNA ▼ -18.0% - Ernexa Therapeutics Inc.

CP $3.50▲ -18.0%Sep 15, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology St…

News

ERNA ▲ +0.7% - Ernexa Therapeutics Inc.

CP $4.20▲ +0.7%Sep 14, 2026 · ThinkSabio Blog

$ERNA - Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference…